Ptc Therapeutics (PTCT) Change in Receivables (2012 - 2026)

Ptc Therapeutics' Change in Receivables history runs 15 years deep, the most recent figure standing at $40.4 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 15.49% year-over-year to $40.4 million; the TTM figure through Mar 2026 stood at $2.7 million (down 58.09% YoY), while the FY2025 annual figure was $10.2 million, up 686.09% from the prior year.
• Change in Receivables was $40.4 million for Q1 2026 at Ptc Therapeutics, up from -$22.2 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $47.8 million in Q1 2025 to a low of -$40.8 million in Q4 2024.
• Historically, Change in Receivables has averaged $5.8 million across 5 years, with a median of $1.2 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Change in Receivables slumped 2258.37% in 2023, then jumped 194.89% in 2024.
• A 5-year view of Change in Receivables shows it stood at $23.7 million in 2022, then slumped by 135.23% to -$8.3 million in 2023, then plunged by 388.27% to -$40.8 million in 2024, then soared by 45.5% to -$22.2 million in 2025, then surged by 281.82% to $40.4 million in 2026.
• The last three Change in Receivables figures came in at $40.4 million (Q1 2026), -$22.2 million (Q4 2025), and $6.5 million (Q3 2025), per Business Quant data.